ZARVY

Becotide Inhaler 250 is an original branded medication manufactured by GSK, containing Beclomethasone 250mcg, a potent inhaled corticosteroid (ICS) used for the long-term management of respiratory conditions. It plays a vital role in controlling chronic airway inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD). The metered dose inhaler (MDI) format allows precise, localized delivery of medication to the lungs, ensuring minimal systemic absorption and enhanced respiratory efficacy. As a first-line anti-inflammatory inhaler, Becotide effectively reduces airway swelling, mucus production, and hypersensitivity to allergens and irritants. It is widely used in maintenance therapy to prevent asthma attacks, reduce the frequency of exacerbations in COPD, and manage persistent respiratory symptoms. It is also beneficial for relieving symptoms associated with allergic rhinitis, such as nasal congestion and sneezing, due to its ability to suppress nasal inflammation when inhaled through the airways.

Qvar 100 Autohaler is an original inhaled corticosteroid (ICS) product manufactured by TEVA, containing Beclomethasone Dipropionate 100mcg per dose. Designed for daily use with a breath-actuated Autohaler device, it provides targeted anti-inflammatory action in the lungs, helping to prevent asthma symptoms and maintain long-term respiratory control. Qvar is a controller medication, not intended for rapid relief during asthma attacks.

Onbrez 150 Breezhaler is an original prescription inhalation therapy developed by Novartis, containing Indacaterol 150mcg, a once-daily ultra-long-acting beta-2 agonist (LABA). It is formulated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), offering rapid and sustained bronchodilation that lasts up to 24 hours. Each dose is delivered via a capsule-based Breezhaler® device, ensuring effective and accurate administration of the medication.

Beclate 200 Inhaler is a metered dose inhaler containing Beclomethasone 200mcg, a potent inhaled corticosteroid (ICS) used in the management of various chronic respiratory conditions. It works by directly targeting airway inflammation, reducing the swelling and mucus production in the lungs that contribute to breathing difficulties. This medication is primarily prescribed for the long-term control of asthma and chronic obstructive pulmonary disease (COPD), especially in individuals who require daily anti-inflammatory support to maintain stable respiratory function. Beclate 200 is also beneficial for managing allergic rhinitis symptoms such as sneezing, nasal congestion, and runny nose, offering targeted relief with minimal systemic side effects. By delivering the active medication directly to the lungs or nasal passages, Beclate 200 ensures fast action and sustained symptom control, making it an essential part of respiratory maintenance therapy.

Loftair Inhaler 110/50 mcg is a generic inhalation therapy that combines Indacaterol 110 mcg and Glycopyrronium 50 mcg per capsule, designed for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). This dual-action inhaler leverages the complementary mechanisms of a long-acting beta-2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA) to enhance bronchodilation, thereby improving airflow and reducing respiratory symptoms in individuals with COPD. :contentReference[oaicite:0]{index=0}

Forglyn Plus Inhaler is a triple-action metered dose inhaler (MDI) formulated with Budesonide (160mcg), Formoterol Fumarate (4.8mcg), and Glycopyrrolate (9mcg), specifically designed for the management of chronic obstructive pulmonary disease (COPD) and severe asthma. This inhaler delivers anti-inflammatory, bronchodilatory, and anticholinergic effects, providing long-term control of airway obstruction and inflammation. - Budesonide is a corticosteroid that reduces inflammation and swelling in the airways, preventing respiratory distress. - Formoterol Fumarate is a long-acting beta-2 adrenergic agonist (LABA) that acts as a bronchodilator, relaxing airway muscles and improving airflow for up to 12 hours. - Glycopyrrolate is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine receptors, reducing mucus production and preventing bronchoconstriction. Forglyn Plus Inhaler is recommended for patients suffering from chronic airway diseases such as COPD, emphysema, and severe asthma, ensuring better lung function, fewer exacerbations, and improved breathing efficiency.

Budecort 100 Inhaler is a generic inhaled corticosteroid (ICS) formulation containing Budesonide 100mcg, developed to manage and control persistent respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Budesonide belongs to the class of inhaled corticosteroids, which work by reducing inflammation in the airways, thereby improving airflow and reducing the frequency and severity of respiratory symptoms like wheezing, coughing, and breathlessness. This medication is a cornerstone in maintenance therapy for patients who require regular anti-inflammatory treatment to prevent exacerbations. By targeting the underlying inflammation within the bronchial tubes, Budecort 100 Inhaler promotes long-term respiratory health and symptom stability. It is particularly effective when incorporated early in asthma management or as a part of combination therapy in COPD cases. As an ICS, Budesonide offers the benefit of localized action within the lungs, minimizing systemic side effects common with oral corticosteroids.

Seroflo 50 Inhaler is a combination metered dose inhaler (MDI) containing Fluticasone Propionate 50mcg and Salmeterol 25mcg, developed for the long-term management of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Fluticasone belongs to the inhaled corticosteroid (ICS) class, reducing inflammation in the airways, while Salmeterol is a long-acting beta-2 agonist (LABA) that relaxes bronchial muscles to improve airflow. This dual-action inhaler helps to prevent bronchospasm, control daily symptoms, and reduce the frequency of exacerbations. It is ideal for patients who require both anti-inflammatory maintenance and sustained bronchodilation, particularly when single-agent therapy is insufficient. As a preventive therapy, Seroflo 50 is not intended for acute asthma attacks but is effective in establishing long-term respiratory stability.

Seroflo 250 Ciphaler is a metered-dose inhaler (MDI) formulation containing Fluticasone Propionate 250mcg and Salmeterol 50mcg, developed as a generic alternative to Seretide Evohaler. This fixed-dose combination provides both anti-inflammatory and bronchodilatory effects, offering long-term control for individuals with moderate to severe asthma or COPD (Chronic Obstructive Pulmonary Disease). It is designed for convenient daily maintenance therapy and is equipped with Cipla's Ciphaler device for accurate dose delivery.

Seroflo 500 Ciphaler is a generic fixed-dose combination of Fluticasone Propionate 500mcg, a potent inhaled corticosteroid (ICS), and Salmeterol 50mcg, a long-acting beta-2 agonist (LABA). It is equivalent to Seretide 500 Evohaler and is intended for inhalation via Cipla’s Ciphaler MDI device. This product is indicated for patients requiring high-dose ICS/LABA therapy for the long-term management of severe asthma or advanced COPD.

Nistami Inhaler 110/50 mcg is a generic dry powder inhalation therapy that combines Indacaterol 110mcg and Glycopyrronium 50mcg, formulated to deliver dual bronchodilation for patients with chronic respiratory diseases. Indacaterol is a long-acting β2-adrenergic agonist (LABA), while Glycopyrronium functions as a long-acting muscarinic antagonist (LAMA). This combination synergistically enhances airway smooth muscle relaxation, significantly improving airflow in patients with Chronic Obstructive Pulmonary Disease (COPD) and moderate to severe asthma. As part of the Respiratory Diseases category, Nistami Inhaler is designed for once-daily use, offering sustained bronchodilation to manage Asthma / COPD, Chronic Bronchitis, and as supportive care in conditions with airway hyperresponsiveness, such as post-viral bronchoconstriction following influenza or tonsillitis. The inclusion of both Indacaterol and Glycopyrronium ensures superior symptom control, reducing the need for rescue medications and improving overall respiratory quality of life.

Glycoair Breezhaler 110/50 mcg is a generic inhalation capsule combining Indacaterol (110mcg) and Glycopyrronium (50mcg), designed to provide dual bronchodilation for individuals suffering from chronic obstructive pulmonary disease (COPD) and moderate to severe asthma. Indacaterol acts as a long-acting beta2-adrenergic agonist (LABA), promoting sustained bronchial muscle relaxation, while Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine-induced bronchoconstriction. Together, these two agents synergize to provide prolonged airway dilation, ease of breathing, and significant reduction in respiratory symptoms. This inhaler is particularly useful in patients experiencing bronchitis, asthma/COPD overlap, or post-viral airway reactivity. It may also offer secondary symptomatic relief in respiratory conditions such as post-influenza bronchospasm or lingering airway constriction after tonsillitis, even though it is not a direct antimicrobial agent. It belongs to the Respiratory Diseases category under the subcategories Asthma / COPD and Bronchitis.

Forglyn Inhaler is a combination bronchodilator formulated with Formoterol Fumarate (4.8mcg) and Glycopyrrolate (9mcg), designed for long-term management of chronic obstructive pulmonary disease (COPD). This metered-dose inhaler (MDI) delivers a controlled dose of medication to open the airways, reduce bronchospasms, and improve breathing efficiency. Formoterol is a long-acting beta-2 agonist (LABA) that relaxes airway muscles, allowing for better airflow and prolonged bronchodilation. Glycopyrrolate is an anticholinergic bronchodilator, reducing airway mucus production and preventing bronchoconstriction. Together, these active ingredients enhance respiratory function, reduce exacerbations, and improve exercise tolerance in COPD patients. Forglyn Inhaler is intended for maintenance therapy in moderate to severe COPD and is not a rescue inhaler for immediate relief. It provides 24-hour symptom control, helping patients breathe more comfortably and reduce dependency on short-acting inhalers.

Airz-F Digihaler is a metered-dose inhaler (MDI) formulated with Formoterol Fumarate (4.8mcg) and Glycopyrrolate (9mcg), specifically designed for the long-term management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This inhaler provides dual-action relief by combining a long-acting beta-2 adrenergic agonist (LABA) with a long-acting muscarinic antagonist (LAMA) to improve lung function and enhance respiratory capacity. Formoterol acts as a bronchodilator, helping to relax airway muscles and allow smoother airflow, while Glycopyrrolate works by blocking muscarinic receptors, reducing airway resistance, and preventing mucus overproduction. Together, these components significantly enhance breathing efficiency, reduce COPD exacerbations, and minimize symptoms like wheezing, shortness of breath, and persistent coughing. This medication is intended for daily maintenance therapy and should not be used as a rescue inhaler for acute bronchospasms. Patients who require consistent symptom control and improved exercise tolerance benefit greatly from this combination therapy.

Asthalin 100mcg Inhaler contains Salbutamol (Albuterol) 100mcg, a short-acting beta-2 agonist (SABA) bronchodilator that provides rapid relief from asthma symptoms, bronchospasms, and breathing difficulties. It is commonly used for asthma, chronic obstructive pulmonary disease (COPD), and exercise-induced bronchoconstriction (EIB). Asthalin works by relaxing airway muscles, allowing easier breathing within minutes.